ATL's HDI Digital Ultrasound Is Approved for Breast Indication

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 5
Volume 5
Issue 5

BOTHELL, Wash--A High Definition Imaging (HDI) digital ultrasound system from Advanced Technology Laboratories (ATL) has been granted FDA approval for a new indication--adjuvant use with mammog-raphy and physical examination to help physicians determine if a biopsy is necessary after discovery of a suspicious breast lesion.

BOTHELL, Wash--A High Definition Imaging (HDI) digital ultrasoundsystem from Advanced Technology Laboratories (ATL) has been grantedFDA approval for a new indication--adjuvant use with mammog-raphyand physical examination to help physicians determine if a biopsyis necessary after discovery of a suspicious breast lesion.

The indication for the Ultramark 9 HDI system is based on thefindings of an international multicenter study involving morethan 1,000 women with breast lesions who were undergoing breastbiopsy.

Lesions were classified based on mammography results, then reclassifiedafter an HDI ultrasound examination performed before breast biopsy.

Investigators found that the number of biopsies could be reducedby approximately 40% using ATL's HDI ultrasound system to distinguishbenign from malignant lesions that were indeterminate by mammographyand physical examination.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content